Heart Failure With Preserved Ejection Fraction, Left Ventricular Diastolic Dysfunction
Conditions
Keywords
Heart failure with preserved ejection fraction, Left ventricular end diastolic pressure, Echocardiography
Brief summary
Retrospectively enrolled suspicious of heart failure with preserved ejection fraction (HFpEF) patients who underwent left heart catheterization with the measurement of left ventricular end-diastolic pressure.
Detailed description
Heart failure (HF) with preserved ejection fraction (HFpEF) remains a poorly understood clinical syndrome without effective targeted therapies. The clinical syndrome of HFpEF develops from a complex interaction of several risk factors such as aging, obesity, hypertension, myocardial ischemia, and arterial stiffness that cause organ dysfunction and, ultimately, clinical symptoms. Although the H2FPEF and HFA-PEFF scores have recently been proposed to estimate the probability of HFpEF in patients suffering from unexplained dyspnea, diagnosing HFpEF remains still challenging. The aim of the current registry was to evaluate the role of invasive left heart catheterization with the measurement of left ventricular end-diastolic pressure (LVEDP) in suspicious of HFpEF patients.
Interventions
DIAGNOSTIC_TESTLeft heart catheterization
Patients who underwent left heart catheterization
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Left ventricular ejection fraction \> 50% * Patients who had a symptom and/or signs of heart failure (dyspnea on exertion, chest discomfort, fatigue, dizziness, or ankle edema) * Patients who underwent left heart catheterization with the measurement of left ventricular end-diastolic pressure
Exclusion criteria
* Left ventricular ejection fraction \<50% * Acute coronary syndrome * More than moderate valvular heart disease * Primary cardiomyopathies such as dilated cardiomyopathy and hypertrophic cardiomyopathy, amyloidosis * Pulmonary arterial hypertension * Heart transplantation * Constrictive pericarditis * Stress-induced cardiomyopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rates of Death or re-hospitalization due to heart failure | 10 Years |
Secondary
| Measure | Time frame |
|---|---|
| Rates of All-cause death | 10 Years |
| Rates of Re-hospitalization due to heart failure | 10 Years |
| Rates of Myocardial infarction | 10 Years |
| Rates of Stroke | 10 Years |
Countries
South Korea
Outcome results
None listed